Researchers unveiled a technique called prime assembly (PA) that improves the insertion of large DNA fragments into genomes, targeting a bottleneck that has limited efficient integration of sequences longer than ~400 base pairs. The approach is positioned as a potential expansion for gene therapy and genome engineering workflows where replacing or adding longer functional units is necessary. The development is framed as a leap over traditional editing workflows that often perform better with small edits. By focusing on large insertions, prime assembly could broaden candidate tractability for programs requiring full gene replacement elements, including larger regulatory or coding segments. In the context of the gene therapy pipeline, the key issue is functional delivery: being able to accurately install large therapeutic payloads without introducing excessive off-target changes. While the report does not detail clinical timelines, it directly addresses an engineering limitation that has long shaped which targets companies can realistically pursue.